Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 17, 2023 (filed on May 26, 2023)Insider Name:Takeda Pharmaceutical Co LtdOwnership Type:Indirect OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-1,000,000Price:--
Filings by filing date
-
Apr 17, 2023 (filed on May 26, 2023)Insider Name:Takeda Pharmaceutical Co LtdOwnership Type:Indirect OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-1,000,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 343 Oyster Point Blvd #200 SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://www.calithera.com |
IR: | See website |
Key People | ||
Susan M. Molineaux President, Chief Executive Officer, Co-Founder, Director | Stephanie Wong Chief Financial Officer, Secretary | Emil T. Kuriakose Chief Medical Officer |
Business Overview |
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue. |
Financial Overview |
For the fiscal year ended 31 December 2022, Calithera Biosciences Inc revenues decreased from $9.8M to $0K. Net loss applicable to common stockholders decreased 82% to $21.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development related to asse decrease from $50.9M (expense) to $0K. |
Employees: | 8 as of Mar 15, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2022 |
EBITDA (TTM): | -$41.82M as of Dec 31, 2022 |
Net annual income (TTM): | -$21.29M as of Dec 31, 2022 |
Free cash flow (TTM): | -$43.63M as of Dec 31, 2022 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 4,872,497 as of Mar 24, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |